{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:22:33Z","timestamp":1772119353893,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00467-025-06997-7","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:56:57Z","timestamp":1759748217000},"page":"483-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of alteplase and urokinase in pharmacomechanical thrombolysis of permanent double lumen hemodialysis catheters in children"],"prefix":"10.1007","volume":"41","author":[{"given":"Yuhi","family":"Takagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manami","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3528-6961","authenticated-orcid":false,"given":"Koichi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"6997_CR1","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105 (Suppl 4S): S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2024.01.001","DOI":"10.1016\/j.kint.2024.01.001"},{"key":"6997_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s004670050602","volume":"13","author":"A Sharma","year":"1999","unstructured":"Sharma A, Zilleruelo G, Abitbol C, Montane B, Strauss J (1999) Survival and complications of cuffed catheters in children on chronic hemodialysis. Pediatr Nephrol 13:245\u2013248. https:\/\/doi.org\/10.1007\/s004670050602","journal-title":"Pediatr Nephrol"},{"issue":"4 Suppl 2","key":"6997_CR3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2019.12.001","volume":"75","author":"CE Lok","year":"2020","unstructured":"Lok CE, Huber TS, Lee T et al (2020) KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis 75(4 Suppl 2):S1\u2013S164. https:\/\/doi.org\/10.1053\/j.ajkd.2019.12.001","journal-title":"Am J Kidney Dis"},{"key":"6997_CR4","unstructured":"Genentech Inc. (2019) Cathflo Activase (Alteplase) [prescribing information]. South San Francisco, CA: Genentech, Inc. https:\/\/www.gene.com\/download\/pdf\/cathflo_prescribing.pdf"},{"key":"6997_CR5","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/s1051-0443(07)61965-4","volume":"13","author":"CP Semba","year":"2002","unstructured":"Semba CP, Deitcher SR, Li X, Resnansky L, Tu T, McCluskey ER, COOL Investigators (2002) Treatment of occluded central venous catheters with alteplase: results in 1,064 patients. J Vasc Interv Radiol 13:1199\u20131205. https:\/\/doi.org\/10.1016\/s1051-0443(07)61965-4","journal-title":"J Vasc Interv Radiol"},{"key":"6997_CR6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s1051-0443(07)61575-9","volume":"12","author":"D Ponec","year":"2001","unstructured":"Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER, COOL Investigators (2001) Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial\u2014the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 12:951\u2013955. https:\/\/doi.org\/10.1016\/s1051-0443(07)61575-9","journal-title":"J Vasc Interv Radiol"},{"key":"6997_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/hdi.12391","volume":"20","author":"V Pollo","year":"2016","unstructured":"Pollo V, Dion\u00edzio D, Bucuvic EM, Castro JH, Ponce D (2016) Alteplase vs. urokinase for occluded hemodialysis catheter: a randomized trial. Hemodial Int 20:378\u2013384. https:\/\/doi.org\/10.1111\/hdi.12391","journal-title":"Hemodial Int"},{"key":"6997_CR8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1177\/1129729818819735","volume":"20","author":"RY Tan","year":"2019","unstructured":"Tan RY, Pang SC, Teh SP, Lee KG, Chong TT, Gogna A, Tan CS (2019) Comparison of alteplase and urokinase for pharmacomechanical thrombolysis of clotted hemodialysis access. J Vasc Access 20:502\u2013506. https:\/\/doi.org\/10.1177\/1129729818819735","journal-title":"J Vasc Access"},{"key":"6997_CR9","doi-asserted-by":"publisher","unstructured":"Deitcher SR, Fesen MR, Kiproff PM, Hill PA, Li X, McCluskey ER; Cardiovascular Thrombolytic to Open Occluded Lines (COOL) Trial Investigators (2002) Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the Cardiovascular Thrombolytic to Open Occluded Lines Trial. J Clin Oncol 20:317\u2013324. https:\/\/doi.org\/10.1200\/JCO.20.1.317","DOI":"10.1200\/JCO.20.1.317"},{"key":"6997_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1525-139x.2001.00109.x","volume":"14","author":"GA Beathard","year":"2001","unstructured":"Beathard GA (2001) Catheter thrombosis: the use and complications of catheters for hemodialysis vascular access. Semin Dial 14:441\u2013445. https:\/\/doi.org\/10.1046\/j.1525-139x.2001.00109.x","journal-title":"Semin Dial"},{"key":"6997_CR11","doi-asserted-by":"publisher","unstructured":"Kukita K, Ohira S, Amano I, Naito H, Azuma N, Ikeda K, Kanno Y, Satou T, Sakai S, Sugimoto T, Takemoto Y, Haruguchi H, Minakuchi J, Miyata A, Murotani N, Hirakata H, Tomo T, Akizawa T, Vascular Access Construction and Repair for Chronic Hemodialysis Guideline Working Group, Japanese Society for Dialysis Therapy (2015) 2011 update Japanese Society for Dialysis Therapy Guidelines of Vascular Access Construction and Repair for Chronic Hemodialysis. Ther Apher Dial 19(Suppl 1):1\u201339. https:\/\/doi.org\/10.1111\/1744-9987.12296","DOI":"10.1111\/1744-9987.12296"},{"key":"6997_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1472-8206.1988.tb00652.x","volume":"2","author":"M Samama","year":"1988","unstructured":"Samama M, Nguyen G, Desnoyers P, Lourenco DM, Fretault J, Horellou MH et al (1988) Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro. Fundam Clin Pharmacol 2:509\u2013523. https:\/\/doi.org\/10.1111\/j.1472-8206.1988.tb00652.x","journal-title":"Fundam Clin Pharmacol"},{"key":"6997_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1345\/aph.1Q483","volume":"47","author":"DM Anderson","year":"2013","unstructured":"Anderson DM, Pesaturo KA, Casavant J, Ramsey EZ (2013) Alteplase for the treatment of catheter occlusion in pediatric patients. Ann Pharmacother 47:405\u2013410. https:\/\/doi.org\/10.1345\/aph.1Q483","journal-title":"Ann Pharmacother"},{"key":"6997_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00467-004-1797-1","volume":"20","author":"OF Bamgbola","year":"2005","unstructured":"Bamgbola OF, del Rio M, Kaskel FJ, Flynn JT (2005) Recombinant tissue plasminogen activator infusion for hemodialysis catheter clearance. Pediatr Nephrol 20:989\u2013993. https:\/\/doi.org\/10.1007\/s00467-004-1797-1","journal-title":"Pediatr Nephrol"},{"key":"6997_CR15","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1200\/JCO.2002.07.131","volume":"20","author":"JP Timoney","year":"2002","unstructured":"Timoney JP, Malkin MG, Leone DM, Groeger JS, Heaney ML, Keefe DL et al (2002) Safe and cost-effective use of alteplase for the clearance of occluded central venous access devices. J Clin Oncol 20:1918\u20131922. https:\/\/doi.org\/10.1200\/JCO.2002.07.131","journal-title":"J Clin Oncol"},{"key":"6997_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/aor.12186","volume":"38","author":"ML Mendes","year":"2014","unstructured":"Mendes ML, Castro JH, Silva TN, Barretti P, Ponce D (2014) Effective use of alteplase for occluded tunneled venous catheter in hemodialysis patients. Artif Organs 38:399\u2013403. https:\/\/doi.org\/10.1111\/aor.12186","journal-title":"Artif Organs"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06997-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06997-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06997-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:02:31Z","timestamp":1766523751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06997-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["6997"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06997-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6522893\/v1","asserted-by":"object"}]},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koichi Kamei received research funding from the Public Foundation of Vaccination Research Center and the Taiju Life Social Welfare Foundation. He also received donations from Chugai Pharmaceutical, Teijin Pharma, Kyowa Kirin, Taiho Pharmaceutical, Shionogi, Daiichi Sankyo, and Mitsubishi Tanabe Pharma, as well as lecture fees from Terumo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written informed consent was obtained from the patients\u2019 guardians for the publication of any potentially identifiable images or data included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and was approved by our Centralized Institutional Review Board (CIRB number: 2024\u2013169). Because alteplase was used off-label, approval was also obtained from the Evaluating Committee for New Unapproved Drugs at our hospital (No. 2022\u201324).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}}]}}